CY1114488T1 - Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv - Google Patents

Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv

Info

Publication number
CY1114488T1
CY1114488T1 CY20131100890T CY131100890T CY1114488T1 CY 1114488 T1 CY1114488 T1 CY 1114488T1 CY 20131100890 T CY20131100890 T CY 20131100890T CY 131100890 T CY131100890 T CY 131100890T CY 1114488 T1 CY1114488 T1 CY 1114488T1
Authority
CY
Cyprus
Prior art keywords
preparation
intermediates
microcyclic
hcv
procedures
Prior art date
Application number
CY20131100890T
Other languages
Greek (el)
English (en)
Inventor
Andras Horvath
Dominic John Ormerod
Dominique Paul Michel Depré
Véronique Cerpentier
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of CY1114488T1 publication Critical patent/CY1114488T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/475Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20131100890T 2008-12-23 2013-10-10 Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv CY1114488T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
EP09801447.5A EP2382198B1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
CY1114488T1 true CY1114488T1 (el) 2016-10-05

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100890T CY1114488T1 (el) 2008-12-23 2013-10-10 Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv

Country Status (22)

Country Link
US (2) US8927722B2 (https=)
EP (1) EP2382198B1 (https=)
JP (1) JP5687631B2 (https=)
KR (1) KR101734507B1 (https=)
CN (1) CN102264715B (https=)
AR (1) AR074863A1 (https=)
AU (1) AU2009331530B2 (https=)
BR (1) BRPI0923393B1 (https=)
CA (1) CA2745565C (https=)
CY (1) CY1114488T1 (https=)
DK (1) DK2382198T3 (https=)
ES (1) ES2429013T3 (https=)
HR (1) HRP20130906T1 (https=)
IL (1) IL213246A (https=)
MX (1) MX2011006764A (https=)
PL (1) PL2382198T3 (https=)
PT (1) PT2382198E (https=)
RU (1) RU2016120007A (https=)
SI (1) SI2382198T1 (https=)
SM (1) SMT201300116B (https=)
TW (1) TWI461424B (https=)
WO (1) WO2010072742A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5687631B2 (ja) 2008-12-23 2015-03-18 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツドJanssen Pharmaceuticals,Inc. Hcvのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体
CA2845720A1 (en) 2011-09-22 2013-03-28 Janssen Pharmaceuticals, Inc. Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
TWI574960B (zh) * 2011-10-28 2017-03-21 健生醫藥公司 用於製備大環蛋白酶抑制劑tmc435之中間體的改良方法
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
EA026235B1 (ru) * 2012-06-08 2017-03-31 Джилид Сайэнс, Инк. Макроциклические ингибиторы вирусов flaviviridae
PT2859009T (pt) 2012-06-08 2018-01-18 Gilead Sciences Inc Inibidores macrocíclicos dos vírus flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
PL1713822T3 (pl) 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
CN101146794A (zh) * 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8012939B2 (en) * 2005-07-29 2011-09-06 Tibotec Pharmaceuticals Ltd. Co Macrocyclic inhibitors of hepatitis C virus
DE602008001251D1 (de) * 2007-02-01 2010-06-24 Tibotec Pharm Ltd Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
BRPI0807482A2 (pt) * 2007-02-08 2014-05-13 Tibotec Pharm Ltd Fenilcarbamatos macrocíclicos inibidores de hcv
JP5687631B2 (ja) 2008-12-23 2015-03-18 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツドJanssen Pharmaceuticals,Inc. Hcvのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体

Also Published As

Publication number Publication date
BRPI0923393A2 (pt) 2015-07-28
JP5687631B2 (ja) 2015-03-18
TWI461424B (zh) 2014-11-21
AU2009331530B2 (en) 2015-04-09
AU2009331530A1 (en) 2011-06-23
CA2745565A1 (en) 2010-07-01
SI2382198T1 (sl) 2013-11-29
CA2745565C (en) 2017-03-07
KR20110099048A (ko) 2011-09-05
AR074863A1 (es) 2011-02-16
CN102264715A (zh) 2011-11-30
KR101734507B1 (ko) 2017-05-11
JP2012513381A (ja) 2012-06-14
US20150080577A1 (en) 2015-03-19
PL2382198T3 (pl) 2013-11-29
MX2011006764A (es) 2011-08-03
ES2429013T3 (es) 2013-11-12
EP2382198A1 (en) 2011-11-02
IL213246A (en) 2017-10-31
WO2010072742A1 (en) 2010-07-01
US8927722B2 (en) 2015-01-06
EP2382198B1 (en) 2013-07-10
BRPI0923393B1 (pt) 2018-06-19
CN102264715B (zh) 2015-12-02
HRP20130906T1 (hr) 2013-10-25
PT2382198E (pt) 2013-10-01
HK1164839A1 (zh) 2012-09-28
RU2011130895A (ru) 2013-01-27
SMT201300116B (it) 2013-11-08
US9115077B2 (en) 2015-08-25
US20110257403A1 (en) 2011-10-20
DK2382198T3 (da) 2013-09-30
RU2016120007A (ru) 2018-11-13
IL213246A0 (en) 2011-07-31
TW201033205A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CY1114488T1 (el) Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
CY2017024I2 (el) Παραγωγα αζετιδινης και κυκλοβουτανιου ως αναστολεις των jak
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
HUE056636T2 (hu) Cisz-1,1,1,4,4,4-hexafluor-2-butén azeotróp-jellegû készítményei
CY1118231T1 (el) Συνθεση λιποσωματος
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CR11861A (es) Compuestos organicos
CL2009001452S1 (es) Pieza agarre cabezal de cuchillas.
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
BRPI0914343A2 (pt) composição, produto, uso da composição e método
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
CY1122115T1 (el) Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης
SMP200900065B (it) Derivati ciclizzati come inibitori di EG-5.
DK3348624T3 (da) Sammensætninger, der omfatter hfc-1234yf
CY1115218T1 (el) Αλας οργανικης αμινης 6-φθορο-3-υδροξυ-2-πυραζινοκαρβονιτριλιου και μεθοδος για την παραγωγη αυτου
ATE492546T1 (de) 6-phenyl-1h-imidazoä4,5-cü-pyridin-4- carbonitrilderivate als cathepsin-hemmer
BRPI0814748A2 (pt) Compostos de alditóis substituídos, composições e métodos